Chinese Journal of Clinical Oncology

, Volume 1, Issue 6, pp 404–411 | Cite as

Antisurvivin oligonucleotides promote in vitro cisplatin induction of apoptosis in osteosarcoma cells

  • Daxin Gao
  • Haiyan Zhang
  • Gang Lu
  • Tao Huang
Original Articles



To study the effect of antisense oligonucleotides (ASODN) of survivin, a member of a gene family of inhibitors of apoptosis, on the ability of cisplatin (DDP) to induce apoptosis in osteosarcoma cells.


ASODN of survivin were synthesized and transfected into osteosarcoma OS-732 cells. The effects of ASODN alone, and with DDP as well as the effect of sense oligonucleotides (SODN) with and without DDP were examined. The reverse tanscriptase-polymerase chain reaction (RT-PCR) was utilized to detect the expression of survivin mRNA in each group of OS -732 cells. The cells were examined by flow cytometry (FCM) and staining with acridine orange (AO) to determine the morphology of the cells and the level of apoptosis in each group. The MTT assay was used to estimate the condition of cell growth.


In comparing the cells transfected with ASODN with the control, SODN and DDP groups, we found that the expression of survivin mRNA was significantly decreased (P<0.01), and the level of apoptosis enhanced. ASODN -treated cells appeared atrophic with condensed chromatin, characteristic of typical apoptotic changes. Cell growth was relatively inhibited in the ASODN groups. Furthermore, the apoptotic index (AI) and cell growth-inhibition ratio (IR) were significantly higher in the ASODN+DDP group compared to each group treated with a single agent and compared to the SODN+DDP group.


ASODN can specifically inhibit the expression of the survivin gene in OS -732 cells, and correspondingly suppress survivin function, resulting in an increase in sensitivity to DDP and thus the ability of DDP to induce apoptosis in osteosarcoma cells.


survivin gene antisense oligonucleotide cisplatin osteosarcoma apoptosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lei WD, Mayotte JE, Levitt ML. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res. 1999;19:221–228.PubMedGoogle Scholar
  2. 2.
    Xia CY, Xu ZD, Yuan XC, et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer. 2002; 1: 687–694.Google Scholar
  3. 3.
    Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat. 2002;5:65–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Thornberry NA, Lazebnik Y. Caspase: Enemines within. Science. 1998; 281:1312–1316.PubMedCrossRefGoogle Scholar
  5. 5.
    Grossman D, Kim PJ, Blanc-Brude OP, et al. Transgenic expression of survivin in keratinocytes counteracts UVB — induced apoptosis and cooperates with loss of P53. J Clin Invest. 2001;108:991–999.PubMedCrossRefGoogle Scholar
  6. 6.
    Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998; 273:11177–11182.PubMedCrossRefGoogle Scholar
  7. 7.
    Helin V, Gottikh M, Mishal Z, et al. Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture. Biochem Pharmacol. 1999; 58:95–107.PubMedCrossRefGoogle Scholar
  8. 8.
    Cambell MJ, Dawson M, Koeffler HP. Growth inhibition of DU -145 prostate cancer cells by a Bcl -2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide. Br J Cancer. 1998;77:739–744.Google Scholar
  9. 9.
    Yuen AR, Branimir LS. Clinical studies of antisense therapy in cancer. Front Biosci. 2000;5:D588–593.PubMedCrossRefGoogle Scholar
  10. 10.
    Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805–2809.PubMedGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer 2004

Authors and Affiliations

  • Daxin Gao
    • 1
  • Haiyan Zhang
    • 2
  • Gang Lu
    • 1
  • Tao Huang
    • 1
  1. 1.Department of Orthopaedics, the First Affiliated HospitalChina Medical UniversityShenyangChina
  2. 2.Department of Endocrinology, the First Affiliated HospitalChina Medical UniversityShenyangChina

Personalised recommendations